Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $53

Benzinga Newsdesk www.benzinga.com Positive 84.7%

Neg 0% Neu 0% Pos 84.7%

Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $48 to $53.